VACSERA collaborating with Bilthoven Biologicals
A significant milestone for Egypt’s self-sufficiency on polio vaccines was reached on October 21st with the signing of the tech transfer agreement between VACSERA and Bilthoven Biologicals. The signing took place on the sidelines of Egypt’s second edition of the Global Congress on Population, Health and Human Development 2024, held under the auspices of President Abdel Fattah Al-Sisi, with the slogan “Human Development: For a Sustainable Future.”
Egypt’s Deputy Prime Minister and Minister of Health and Population, Khaled Abdel Ghaffar, witnessed the signing of a cooperation agreement between the Holding Company for Biological Products and Vaccines (VACSERA) and the Dutch company Bilthoven Biologicals (BBio) to transfer the technology of manufacturing the injectable polio vaccine.
Basil Babychan, Commercial director at BBio: “What we are doing is to bring the technology to Egypt, where the product is filled, finished and supplied in the Egyptian market through VACSERA”. Jurgen Kwik, CEO at BBio adds: “This development aligns with BBio’s mission to be at the forefront of the fight against polio and achieve polio eradication. It’s a great pleasure to bring this announcement today, on World Polio Day 2024”.
Hossam Abdel Ghaffar, spokesperson for the Ministry of Health and Population of Egypt, explained that Bilthoven Biologicals is one of the leading Dutch companies in the field of transferring vaccine manufacturing technology, and this is the first time the company has transferred vaccine manufacturing technology outside Europe, in addition to the company providing all means of support in the steps of qualifying the vaccine to comply with good manufacturing conditions to ensure quality.
Sherif Al-Feel, Managing Director of the Holding Company for Biological Products and Vaccines (VACSERA), said that the injectable polio vaccine is one of the vaccines used to keep Egypt free of polio, adding that signing the cooperation agreement is a step towards localizing the vaccine industry and achieving self-sufficiency in the injectable polio vaccine, with the possibility of exporting the product to African countries. VACSERA is the state led producer of sera and vaccines in Egypt.
UtrechtInc has been recognized in the Financial Times “Europe’s Leading Startup Hubs 2026” ranking.
While UtrechtInc is proud of this recognition, the real stars of the story are the entrepreneurs, researchers, and students who walk through its doors every day.
Are you participating in the Utrecht Marathon or are you a keen runner? Register for the Running Symposium on March 19th.
On Sunday, May 31st, Utrecht Science Park will once again be the setting for the Utrecht Marathon. Thousands of runners will line up at the starting line to achieve a fantastic feat: running a quarter, half, or full marathon! To help you prepare optimally, the Utrecht Science Park Foundation, in collaboration with partners Utrecht University, UMC Utrecht, Utrecht University of Applied Sciences, and Olympos Sports Centre, is organizing a running symposium where you’ll be informed and inspired to get the most out of your running performance.
Applications Now Open for UtrechtInc Validation Programmes
Have you ever wondered what it takes to turn research or an idea into a startup? The validation programmes offered by UtrechtInc may provide the first step. Applications are now open.
Utrecht Science Park researchers receive prestigious Cancer Grand Challenge grants
Several research groups, including researchers from UMC Utrecht, the Princess Máxima Center, and the Hubrecht Institute, have been selected for a prestigious Cancer Grand Challenge (CGC) grant. Cancer Grand Challenges was co-founded in 2020 by Cancer Research UK and the National Cancer Institute in the United States. The initiative supports international, multidisciplinary research teams focusing on major challenges in cancer research.